<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02649309</url>
  </required_header>
  <id_info>
    <org_study_id>PMK-SCRIP</org_study_id>
    <nct_id>NCT02649309</nct_id>
  </id_info>
  <brief_title>Single-cycle Remote Ischemic Preconditioning and Postconditioning (SCRIP) Trial</brief_title>
  <acronym>SCRIP</acronym>
  <official_title>Effect of Single-cycle Remote Ischemic Preconditioning and Postconditioning on Myocardial Injury in Patients Undergoing Emergency and Elective Percutaneous Intervention in Phramongkutklao Hospital and Thammasat University</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Phramongkutklao College of Medicine and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Phramongkutklao College of Medicine and Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a 2 x 2 factorial design, double-blinded, randomized controlled trial to
      evaluate efficacy and safety of remote ischemic preconditioning and postconditioning in
      patient undergoing coronary angioplasty.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in cardiac Troponin-T from baseline</measure>
    <time_frame>within 24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of myocardial injury</measure>
    <time_frame>within 24 hours</time_frame>
    <description>Incidence of myocardial injury defined as &gt; 5 times elevation of cardiac troponin from baseline in patients with normal baseline troponin and elevation of cardiac troponin &gt; 20% in patients who have elevated baseline troponin (&gt;99 percentile upper reference limit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiovascular events (MACE) in each intervention group</measure>
    <time_frame>6 months</time_frame>
    <description>MACE = composite of CV death, MI, stroke, repeat revascularization, hospitalization for heart failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of myocardial injury in differrent subgroups of patient characteristics</measure>
    <time_frame>within 24 hours</time_frame>
    <description>Patient characteristics include sex, age, underlying disease, medications, indication for PCI (ACS and elective PCI), baseline cardiac enzyme and creatinine. Incidence of myocardial injury defined as &gt; 5 times elevation of cardiac troponin from baseline in patients with normal baseline troponin and elevation of cardiac troponin &gt; 20% in patients who have elevated baseline troponin (&gt;99 percentile upper reference limit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of myocardial injury in patients with vs. without RIPre and RIPost</measure>
    <time_frame>24 hours</time_frame>
    <description>Myocardial injury defined as &gt; 5 times elevation of cardiac troponin from baseline in patients with normal baseline troponin and elevation of cardiac troponin &gt; 20% in patients who have elevated baseline troponin (&gt;99 percentile upper reference limit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of MACE in differrent subgroups of patient characteristics</measure>
    <time_frame>6 months</time_frame>
    <description>Patient characteristics include sex, age, underlying disease, medications, indication for PCI (ACS and elective PCI), baseline cardiac enzyme and creatinine.
MACE = composite of CV death, MI, stroke, repeat revascularization, hospitalization for heart failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of MACE in patients with vs. without RIPre and RIPost</measure>
    <time_frame>6 months</time_frame>
    <description>Patient characteristics include sex, age, underlying disease, medications, indication for PCI (ACS and elective PCI), baseline cardiac enzyme and creatinine.
MACE = composite of CV death, MI, stroke, repeat revascularization, hospitalization for heart failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of MACE in patients who have myocardial injury vs. patients who have no myocardial injury</measure>
    <time_frame>6 months</time_frame>
    <description>Myocardial injury defined as &gt; 5 times elevation of cardiac troponin from baseline in patients with normal baseline troponin and elevation of cardiac troponin &gt; 20% in patients who have elevated baseline troponin (&gt;99 percentile upper reference limit).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">370</enrollment>
  <condition>Ischemic Reperfusion Injury</condition>
  <arm_group>
    <arm_group_label>RIPre + RIPost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: RIPre 200 mmHg + RIPost 200 mmHg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RIPre + Sham</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: RIPre 200 mmHg + Sham 10 mmHg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham + RIPost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Sham 10 mmHg + RIPost 200 mmHg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham + Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Intervention: Sham 10 mmHg + Sham 10 mmHg</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>RIPre</intervention_name>
    <description>Preconditioning 200 mmHg x 5 minutes before procedure</description>
    <arm_group_label>RIPre + RIPost</arm_group_label>
    <arm_group_label>RIPre + Sham</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham-Pre</intervention_name>
    <description>Sham 10 mmHg x 5 minutes before procedure</description>
    <arm_group_label>Sham + RIPost</arm_group_label>
    <arm_group_label>Sham + Sham</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>RIPost</intervention_name>
    <description>Postconditioning 200 mmHg x 5 minutes after procedure</description>
    <arm_group_label>RIPre + RIPost</arm_group_label>
    <arm_group_label>Sham + RIPost</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham-Post</intervention_name>
    <description>Sham 10 mmHg x 5 minutes after procedure</description>
    <arm_group_label>RIPre + Sham</arm_group_label>
    <arm_group_label>Sham + Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eligible for percutaneous coronary intervention (elective and emergency cases)

          -  Age &gt; 18-year-old

          -  Informed consent

        Exclusion Criteria:

          -  Previous CABG

          -  Previous PCI in 1 week / treatment with thrombolysis within 30 days

          -  Peripheral arterial disease / A-V shunt of upper extremities (AVF for hemodialysis)

          -  Paresis of upper limb

          -  Unstable patient such as cardiogenic shock / vasopressor / IABP / cooling
             (hypothermia)

          -  Fatal cardiac arrhythmia (VT / VF)

          -  Chronic hypoxia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nakarin Sansanayudh, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Internal Medicine, Phramongkutklao Hospital, Bangkok, Thailand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nakarin Sansanayudh, MD,PhD</last_name>
    <phone>+6627639300</phone>
    <phone_ext>93807</phone_ext>
    <email>dr_nakarin@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kitcha Champasri, MD</last_name>
    <phone>+66897146999</phone>
    <email>dr.kitcha@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Internal Medicine</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nakarin Sansanayudh, MD,PhD</last_name>
      <phone>+6623547600</phone>
      <phone_ext>93827</phone_ext>
      <email>dr_nakarin@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Kitcha Champasri, MD</last_name>
      <phone>+66897146969</phone>
      <email>dr.kitcha@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2015</study_first_submitted>
  <study_first_submitted_qc>January 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2016</study_first_posted>
  <last_update_submitted>April 5, 2018</last_update_submitted>
  <last_update_submitted_qc>April 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ischemic Preconditioning</keyword>
  <keyword>Postconditioning</keyword>
  <keyword>Angioplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Reperfusion Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

